Whether vorasidenib-VORANIGO has been included in medical insurance and details of policy updates and reimbursement conditions

Vorasidenib (trade name VORANIGO) is a new oral small molecule IDH1/2 inhibitor, mainly used to treat patients with gliomas and some other solid tumors carrying IDH mutations. The drug selectively inhibits IDH1/2 enzyme activity and blocks abnormal metabolic pathways of tumor cells, thereby inhibiting tumor growth. Due to its high targeting specificity, clinical trials have shown that vorsidenib has potential efficacy in relapsed or refractory patients, but it is still not available in the domestic market.

In terms of medical insurance inclusion, vorsidenib has not yet been officially launched in China, so it is naturally not included in the national medical insurance reimbursement catalog. Domestic patients are temporarily unable to obtain the drug through medical insurance channels, and there is no unified domestic selling price. If patients need to use vorsidenib, they can only purchase the drug through formal overseas channels or participate in international multi-center clinical trials to obtain treatment opportunities. It should be noted that there are legal and safety risks in obtaining drugs through informal channels. Patients must ensure the safety and efficacy of medication under the guidance of professional doctors.

Pricing information from overseas markets shows that the US version of the original version of Voxanib is 40mg*30 tablets, and each box is priced at approximately 38 RMB, which shows its high cost and market positioning as an innovative drug. At the same time, there are also generic drug options, such as voxanib of the same specification produced by Lucius Pharmaceuticals in Laos. Each box is priced at more than 7,000 yuan, and the drug ingredients are basically the same as the original drug. The price advantage of this type of generic drugs is obvious, but it is still necessary to ensure that the drug purchase channels are formal and legal, and to avoid using drugs without regulatory approval.

Future updates to medical insurance policies will directly affect the accessibility of voxanib in the country. Considering that it is an innovative targeted drug, if it is officially launched in China, it is expected to be initially included in the medical insurance negotiation catalog through specific disease types or patient groups. Reimbursement conditions may include patients with positive genetic test results, failure of previous standard treatments, and patients who meet clinical trials or specific indications. With the advancement of domestic approval for marketing and medical insurance policies, patients' opportunities to obtain vorsidenib treatment will gradually increase, but before that, they still need to obtain it through formal overseas channels or clinical trials, and strictly abide by doctor's guidance.

Reference materials:https://www.drugs.com/